Evidence map›Paper›PMID 31516745›Full record

ArticleCancer biology & medicine2019

Identification of anticancer drugs to radiosensitise

Rebecca Carter, Azadeh Cheraghchi-Bashi, Adam Westhorpe, Sheng Yu, Yasmin Shanneik, Elena Seraia, Djamila Ouaret, Yasuhiro Inoue, Catherine Koch, Jenny Wilding and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 3 countries.

Rebecca CarterNIHR University College London Hospitals Biomedical Research Centre, UCL Cancer Institute, University College London, London WC1E 6DD, UK.
Azadeh Cheraghchi-BashiNIHR Oxford Biomedical Research Centre, Department of Oncology, University of Oxford, Oxford OX1 2JD, UK.
Adam WesthorpeNIHR University College London Hospitals Biomedical Research Centre, UCL Cancer Institute, University College London, London WC1E 6DD, UK.
Sheng YuComputational Biology and Integrative Genomics, University of Oxford, Oxford OX1 2JD, UK.
Yasmin ShanneikNIHR Oxford Biomedical Research Centre, Department of Oncology, University of Oxford, Oxford OX1 2JD, UK.
Elena SeraiaNDM Research Building, Nuffield Department of Medicine, University of Oxford, Oxford OX1 2JD, UK.
Djamila OuaretWeatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX1 2JD, UK.
Yasuhiro InoueMie University, Graduate School of Medicine, Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Edobashi 2-174, Tsu, Japan.
Catherine KochDepartment of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA.
Jenny WildingWeatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX1 2JD, UK.
Daniel EbnerTarget Discovery Institute, National Phenotypic Screening Centre, Nuffield Department of Medicine, University of Oxford, Oxford OX1 2JD, UK.
Anderson J RyanCRUK & MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford OX1 2JD, UK.
Francesca M BuffaCRUK & MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford OX1 2JD, UK.
Ricky A SharmaNIHR University College London Hospitals Biomedical Research Centre, UCL Cancer Institute, University College London, London WC1E 6DD, UK.
University of Oxford · GBJohn Radcliffe Hospital · GBMassachusetts Institute of Technology · USMie University · JP

Funding

Cancer Research UK 23969Medical Research Council MC_PC_12006Medical Research Council MC_UU_00001/6
6 · The paper itself

Abstract

objectivePatients with

methodsWe screened 298 oncological drugs with and without ionising radiation in colorectal cancer cells isogenic for

resultsMost consistently identified hits were drugs targeting cell growth/proliferation or DNA damage repair. The most effective class of drugs that radiosensitised wild-type and mutant cell lines was PARP inhibitors. In clonogenic survival assays, talazoparib produced a radiation enhancement ratio of 1.9 in DLD1 (

conclusionsOur method for screening large drug libraries for radiosensitisation has identified PARP inhibitors as promising radiosensitisers of colorectal cancer cells with wild-type and mutant

Indexed as

colorectal cancerPARP inhibitorRadiosensitizerradiotherapy

Identifiers

PMID31516745
PMCPMC6713640
OpenAlexW2948079813

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.